AL
Astellas Pharma Inc.
ALPMF · OTC
$15.85 +2.59% (+$0.40)
1M +0.32%
Market Cap ¥4.13T
P/E Ratio 11.31x
Div. Yield 3.44%
ROE 20.38%
Bulios Fair Price
$10.06
36.5% downside
Current Price
$15.85
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALPMF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
97 /100
Cheap P/E 11.31x
P/FCF 7.59x
EV/EBITDA 6.34x
Growth
32 /100
Declining EPS growth 25.04%
Book val. growth 1.19%
Rev. growth 13.84%
Profitability
95 /100
Strong Gross margin 74.71%
FCF margin 23.86%
Net margin 16.01%
Quality
79 /100
Excellent ROIC 14.16%
Asset turnover 0.62x
ROE 20.38%
Debt
93 /100
Low Debt/Equity 0.30x
Net debt/EBITDA 0.49x
Current ratio 1.20x
Stability
45 /100
Moderate Beta 0.09x
Profitable years 6
Rev. volatility 7.35%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALPMF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Naoki Okamura
Employees
14,099
Headquarters
Tokyo
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
29 SEP
Dividend Payment
Payment date
04 NOV
Earnings
Upcoming earnings report
30 MAR
Ex-Dividend
Ex-dividend date
30 MAR
Dividend Payment
Payment date